G Coll1, J-D Combes2, F Isfan3, E Rochette3, J Chazal4, J-J Lemaire4, E de Schlichting5, J Kanold6. 1. Service de neurochirurgie, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, BP 69, 58, rue Montalembert, 63001 Clermont-Ferrand, France; Université Clermont Auvergne, université d'Auvergne, BP 10448, 63000 Clermont-Ferrand, France. Electronic address: gcoll@chu-clermontferrand.fr. 2. International Agency for Research on Cancer, 69372 Lyon, France. 3. Centre régional de cancérologie et thérapie cellulaire pédiatrique, hôpital Estaing, CHU de Clermont-Ferrand, 63001 Clermont-Ferrand, France; Unité CRECHE Inserm-CIC 1405, 63003 Clermont-Ferrand, France. 4. Service de neurochirurgie, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, BP 69, 58, rue Montalembert, 63001 Clermont-Ferrand, France; Université Clermont Auvergne, université d'Auvergne, BP 10448, 63000 Clermont-Ferrand, France. 5. Service de neurochirurgie, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, BP 69, 58, rue Montalembert, 63001 Clermont-Ferrand, France. 6. Centre régional de cancérologie et thérapie cellulaire pédiatrique, hôpital Estaing, CHU de Clermont-Ferrand, 63001 Clermont-Ferrand, France; Unité CRECHE Inserm-CIC 1405, 63003 Clermont-Ferrand, France; Université Clermont Auvergne, université d'Auvergne, BP 10448, 63000 Clermont-Ferrand, France.
Abstract
INTRODUCTION: Central nervous system tumors (CNST) are the most lethal of solid tumors in childhood cancer. PATIENTS AND METHODS: We report incidence and survival data for all CNST (International Classification of Diseases for Oncology third edition, category III or Xa) recorded in children under 15 years of age by the Auvergne-Limousin cancer registry for the period 1986-2009. RESULTS: Annual incidence of all CNST was 3.27 per 100,000 and the male to female ratio was 0.95. Over 45.0% of CNST were glial. Astrocytomas (36.2%) showed the highest incidence for each age group except between 1 and 4 years where embryonal tumors were more common. For all CNST, no significant variation in incidence over time was observed for the evaluated period of 23 years (annual percent change: -0.4%, 95% CI, [-2.8-2.1]). Globally, 5 years overall survival was 67% [59-73] and had increased by more than 16% between 1986-1999 and 2000-2009, mainly due to better survival for astrocytomas, other gliomas, ependymomas and choroid plexus tumors (P=0.01). CONCLUSION: We report that the incidence of CNST in Auvergne-Limousin is similar to that in the literature and did not increase between 1986 and 2009. In addition, 5 years overall survival increased after 1999, especially for surgically treatable tumors.
INTRODUCTION:Central nervous system tumors (CNST) are the most lethal of solid tumors in childhood cancer. PATIENTS AND METHODS: We report incidence and survival data for all CNST (International Classification of Diseases for Oncology third edition, category III or Xa) recorded in children under 15 years of age by the Auvergne-Limousin cancer registry for the period 1986-2009. RESULTS: Annual incidence of all CNST was 3.27 per 100,000 and the male to female ratio was 0.95. Over 45.0% of CNST were glial. Astrocytomas (36.2%) showed the highest incidence for each age group except between 1 and 4 years where embryonal tumors were more common. For all CNST, no significant variation in incidence over time was observed for the evaluated period of 23 years (annual percent change: -0.4%, 95% CI, [-2.8-2.1]). Globally, 5 years overall survival was 67% [59-73] and had increased by more than 16% between 1986-1999 and 2000-2009, mainly due to better survival for astrocytomas, other gliomas, ependymomas and choroid plexus tumors (P=0.01). CONCLUSION: We report that the incidence of CNST in Auvergne-Limousin is similar to that in the literature and did not increase between 1986 and 2009. In addition, 5 years overall survival increased after 1999, especially for surgically treatable tumors.
Keywords:
Cancer; Central nervous system tumors; Childhood; Descriptive epidemiology; Pédiatrie; Sex ratio; Sex-ratio; Survie; Survival; Tumeurs du système nerveux central; Épidémiologie descriptive
Authors: E Story; D L Johnston; U Bartels; A S Carret; B Crooks; D D Eisenstat; C Fryer; L Lafay-Cousin; V Larouche; B Wilson; S Zelcer; M Silva; J Brossard; E Bouffet; D L Keene Journal: J Neurooncol Date: 2017-05-16 Impact factor: 4.130
Authors: S Rivas-Vilela; J Rubió-Casadevall; A Fàbrega-Ribas; C Joly-Torta; L Vilardell; R Marcos-Gragera Journal: Clin Transl Oncol Date: 2019-02-02 Impact factor: 3.405